



**News Release Dated March 12, 2018**

MEDRx Co., Ltd.  
Yonehiro Matsumura, President & CEO  
Stock code: 4586, TSE Mothers

## **Patent Granted in the United States for a Transdermal Drug with Acid Scavenger**

MEDRx Co., Ltd. received notification from its agent on March 12, 2018 that the United States Patent and Trademark Office (USPTO) has approved its patent application regarding a transdermal drug with acid scavenger.

This patent, which will expire in 2035, is one of the key patents for MRX-1OXT, a transdermal patch with oxycodone\* for alleviating central pain.

This patent is also valid in Japan and applications have been submitted in Europe and China.

This patent will have no effect on the MEDRx Group's results of operations in 2018.

<Reference>

\* Oxycodone

Oxycodone is a type of central analgesic (acts on the central nerves in the brain and the spinal cord to relieve pain) and is a designated narcotic drug for medical use. It is used for relieving severe acute pain, chronic pain, and cancer pain.

MRX-1OXT is a transdermal patch that utilizes the ILTS® (Ionic Liquid Transdermal System), MEDRx's exclusive drug absorption technology using ionic liquids, to significantly improve transdermal delivery of poorly absorbable oxycodone and is also safe for application on the skin. MRX-1OXT also uses the abuse and misuse resistant transdermal system (AMRTS®), an exclusive MEDRx technology newly developed for producing drugs absorbed through the skin. The aim of this technology is to reduce and prevent the improper and erroneous use of oxycodone, which is designated as a narcotic drug for medical use.

-----  
Contact:  
MEDRx Co., Ltd.  
Management Department  
E-mail: info@medrx.co.jp  
-----